Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection
about
mRNA decay during herpes simplex virus (HSV) infections: protein-protein interactions involving the HSV virion host shutoff protein and translation factors eIF4H and eIF4A.A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunityProtection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.The virion host shutoff protein of herpes simplex virus 1 blocks the replication-independent activation of NF-κB in dendritic cells in the absence of type I interferon signaling.Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1Recurrent herpetic stromal keratitis in mice: a model for studying human HSK.Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in MiceImpaired Fas-Fas Ligand Interactions Result in Greater Recurrent Herpetic Stromal Keratitis in Mice.Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.mRNA decay during herpes simplex virus (HSV) infections: mutations that affect translation of an mRNA influence the sites at which it is cleaved by the HSV virion host shutoff (Vhs) protein.Recurrent herpetic stromal keratitis in mice, a model for studying human HSK.Small interfering RNAs that deplete the cellular translation factor eIF4H impede mRNA degradation by the virion host shutoff protein of herpes simplex virusProphylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusDelivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways.High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.CXCL1 but not IL-6 is required for recurrent herpetic stromal keratitis.Prior Corneal Scarification and Injection of Immune Serum are Not Required Before Ocular HSV-1 Infection for UV-B-Induced Virus Reactivation and Recurrent Herpetic Corneal Disease in Latently Infected Mice.Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculationCXCL9 compensates for the absence of CXCL10 during recurrent Herpetic stromal keratitis.
P2860
Q24532995-D2D34827-BE2B-4C3A-BBE6-F9CD9C3B0A1FQ33964131-501453DF-9A6A-48EC-83D1-B8A61DD56A48Q34150713-FCE953D8-26E8-4F84-BBFF-4E4D7F0C1EC9Q34520389-F9F036AF-2A6B-425B-8284-74430D9A6937Q35020742-4FE0498B-8A14-4430-938B-4B6764F586C2Q35531680-FF3ABFC9-C004-4B25-BB87-60D9480CF6DEQ35658941-3FCFA71A-B02D-4044-AB65-47E1E3845409Q35944884-A12C4B43-CC82-485B-8228-68FD009B2B23Q36124928-44C70DE8-089A-4F1F-BFE1-483701CC491CQ36173155-54001A8C-3F1A-400F-B01D-92EDC4DF951FQ36199997-390D36A3-168F-43C2-9F4A-5AFC5402BE38Q36506791-BB550654-0BDA-44DF-9137-4A90FF0C56E6Q36621642-69B7998A-9289-4A12-BF3F-ECE8765D71C1Q36747970-6096E7E2-0B3C-46C1-8A83-50BC92EDB814Q36879345-E3EF8D4C-CD67-4F0A-B0B4-89C43561F7BFQ37061759-7776B4DC-D4E1-4893-BAF0-D4A2A0E8982FQ37160338-AAA98CB7-14E3-4422-93EF-593E8E283F83Q37623874-5270FEC8-A10A-42B6-BE65-D1AE91B9395AQ37699104-B599CA80-0BDF-4F44-8FB8-89EA6C82244EQ39736622-4C270D08-E66D-4907-BF38-587AF56F4BC6Q40297879-67D2D3DB-1724-4C2F-8ACF-8F582C031D75
P2860
Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Therapeutic immunization with ...... rent herpetic ocular infection
@ast
Therapeutic immunization with ...... rent herpetic ocular infection
@en
Therapeutic immunization with ...... rent herpetic ocular infection
@nl
type
label
Therapeutic immunization with ...... rent herpetic ocular infection
@ast
Therapeutic immunization with ...... rent herpetic ocular infection
@en
Therapeutic immunization with ...... rent herpetic ocular infection
@nl
prefLabel
Therapeutic immunization with ...... rent herpetic ocular infection
@ast
Therapeutic immunization with ...... rent herpetic ocular infection
@en
Therapeutic immunization with ...... rent herpetic ocular infection
@nl
P2093
P2860
P1433
P1476
Therapeutic immunization with ...... rent herpetic ocular infection
@en
P2093
Jay S Pepose
Jessica L Morris
Lynda A Morrison
Patrick M Stuart
Tammie L Keadle
P2860
P304
P356
10.1128/JVI.76.8.3615-3625.2002
P407
P577
2002-04-01T00:00:00Z